17:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
21:36 , Sep 17, 2018 |  BC Extra  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) had a busy Monday announcing the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp....
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

PA101: Phase II data

Top-line data from a double-blind, crossover, U.K. and Dutch Phase II trial in 24 IPF patients with refractory chronic cough showed that thrice-daily 40 mg inhaled PA101 delivered via the eFlow nebulizer system reduced average...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

PA101B: Phase II started

Patara began a double-blind, placebo-controlled, crossover, European Phase II trial to evaluate 40 mg inhaled PA101B delivered via eFlow nebulizer thrice daily for 14 days in about 48 patients with refractory chronic cough, including those...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

PA101B: Phase II started

Patara began the European Phase II ISM2 Study to evaluate 40 mg inhaled PA101B delivered via eFlow nebulizer thrice daily for 6 weeks in about 36 patients. The trial comprises a double-blind, placebo-controlled, crossover portion,...
01:05 , Oct 13, 2015 |  BC Extra  |  Financial News

Patara raises $26M, starts Phase II studies

Patara Pharma Inc. (San Diego, Calif.) raised $26 million in a series A round and began two Phase II trials of PA101B , an agonist of G protein-coupled receptor 35 ( GPR35 ) that stabilizes...